Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
MYL's Cash to Debt is ranked lower than
59% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. MYL: 0.03 )
MYL' s 10-Year Cash to Debt Range
Min: 0.03   Max: 44.56
Current: 0.03

0.03
44.56
Equity to Asset 0.21
MYL's Equity to Asset is ranked lower than
55% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. MYL: 0.21 )
MYL' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.92
Current: 0.21

0.19
0.92
Interest Coverage 3.62
MYL's Interest Coverage is ranked lower than
52% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. MYL: 3.62 )
MYL' s 10-Year Interest Coverage Range
Min: 0.83   Max: 9.19
Current: 3.62

0.83
9.19
F-Score: 8
Z-Score: 1.87
M-Score: -2.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 16.44
MYL's Operating margin (%) is ranked higher than
86% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. MYL: 16.44 )
MYL' s 10-Year Operating margin (%) Range
Min: 2.31   Max: 36
Current: 16.44

2.31
36
Net-margin (%) 9.03
MYL's Net-margin (%) is ranked higher than
77% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. MYL: 9.03 )
MYL' s 10-Year Net-margin (%) Range
Min: -3.53   Max: 30.52
Current: 9.03

-3.53
30.52
ROE (%) 21.20
MYL's ROE (%) is ranked higher than
96% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MYL: 21.20 )
MYL' s 10-Year ROE (%) Range
Min: -6.7   Max: 25.05
Current: 21.2

-6.7
25.05
ROA (%) 4.09
MYL's ROA (%) is ranked higher than
73% of the 748 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. MYL: 4.09 )
MYL' s 10-Year ROA (%) Range
Min: -1.74   Max: 22.13
Current: 4.09

-1.74
22.13
ROC (Joel Greenblatt) (%) 34.10
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. MYL: 34.10 )
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.09   Max: 90.88
Current: 34.1

4.09
90.88
Revenue Growth (%) 1.90
MYL's Revenue Growth (%) is ranked higher than
63% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. MYL: 1.90 )
MYL' s 10-Year Revenue Growth (%) Range
Min: -6.1   Max: 54.5
Current: 1.9

-6.1
54.5
EBITDA Growth (%) 5.90
MYL's EBITDA Growth (%) is ranked higher than
70% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. MYL: 5.90 )
MYL' s 10-Year EBITDA Growth (%) Range
Min: -20   Max: 107
Current: 5.9

-20
107
EPS Growth (%) 32.40
MYL's EPS Growth (%) is ranked higher than
89% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. MYL: 32.40 )
MYL' s 10-Year EPS Growth (%) Range
Min: -28.8   Max: 110.4
Current: 32.4

-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MYL Guru Trades in Q3 2013

Caxton Associates 200,000 sh (New)
John Paulson 12,139,300 sh (unchged)
Mario Gabelli 13,000 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Jim Simons Sold Out
Ray Dalio Sold Out
Scott Black 359,799 sh (-4.89%)
Paul Tudor Jones 431,700 sh (-7.18%)
John Hussman 454,000 sh (-43.25%)
Steven Cohen 524,317 sh (-50.24%)
Joel Greenblatt 10,695 sh (-91.73%)
» More
Q4 2013

MYL Guru Trades in Q4 2013

David Dreman 1,221 sh (New)
John Paulson 12,139,300 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Mario Gabelli 13,000 sh (unchged)
Caxton Associates Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 519,430 sh (-0.93%)
Scott Black 307,214 sh (-14.62%)
Joel Greenblatt 7,291 sh (-31.83%)
John Hussman 200,000 sh (-55.95%)
» More
Q1 2014

MYL Guru Trades in Q1 2014

Jim Simons 1,401,474 sh (New)
Paul Tudor Jones 432,717 sh (New)
Andreas Halvorsen 1,776,108 sh (New)
Jean-Marie Eveillard 675,428 sh (New)
Louis Moore Bacon 134,160 sh (New)
Steven Cohen 553,164 sh (+6.49%)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Mario Gabelli 13,000 sh (unchged)
David Dreman Sold Out
Joel Greenblatt Sold Out
John Paulson 12,130,700 sh (-0.07%)
Scott Black 274,571 sh (-10.63%)
John Hussman 50,000 sh (-75%)
» More
Q2 2014

MYL Guru Trades in Q2 2014

Vanguard Health Care Fund 4,775,700 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-03-31 Reduce -75%0.47%$42.26 - $57.2 $ 49.373%50000
Scott Black 2014-03-31 Reduce -10.63%0.16%$42.26 - $57.2 $ 49.373%274571
Jean-Marie Eveillard 2014-03-31 New Buy0.09%$42.26 - $57.2 $ 49.372%675428
Joel Greenblatt 2014-03-31 Sold Out 0.01%$42.26 - $57.2 $ 49.372%0
David Dreman 2014-03-31 Sold Out $42.26 - $57.2 $ 49.372%0
John Hussman 2013-12-31 Reduce -55.95%0.53%$37.865 - $44.5 $ 49.3720%200000
Scott Black 2013-12-31 Reduce -14.62%0.23%$37.865 - $44.5 $ 49.3720%307214
David Dreman 2013-12-31 New Buy$37.865 - $44.5 $ 49.3720%1221
Joel Greenblatt 2013-12-31 Reduce -31.83%$37.865 - $44.5 $ 49.3720%7291
John Hussman 2013-09-30 Reduce -43.25%0.48%$30.37 - $38.95 $ 49.3740%454000
Joel Greenblatt 2013-09-30 Reduce -91.73%0.16%$30.37 - $38.95 $ 49.3740%10695
Ray Dalio 2013-09-30 Sold Out 0.02%$30.37 - $38.95 $ 49.3740%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Mylan Inc

Scott Black’s Top First Quarter Holdings
Scott Black is the chairman, president, chief investment officer and founder of Boston-based Delphi Management, and is often featured in Barron’s. Delphi Management’s investment philosophy states that they “only invest in companies that meet our internally developed set of rigorous quantitative criteria.” The fund also only invests in equity securities of US-listed companies, and takes only long positions. Read more...
S&P Winners Broadly Held by Billionaires
Over 12 months, FLIR Systems Inc. (FLIR) is up 61%, Mylan Inc. (MYL) is up 64% and Nabors Industries Ltd. (NBR) is up 24%, making them three of the biggest winners in the S&P 500. Here’s a company update about the top billionaire stakeholders, as of June 30, 2013. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 30.90
MYL's P/E(ttm) is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. MYL: 30.90 )
MYL' s 10-Year P/E(ttm) Range
Min: 11.01   Max: 113.27
Current: 30.9

11.01
113.27
P/B 5.90
MYL's P/B is ranked higher than
55% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. MYL: 5.90 )
MYL' s 10-Year P/B Range
Min: 0.64   Max: 7.02
Current: 5.9

0.64
7.02
P/S 2.78
MYL's P/S is ranked higher than
72% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. MYL: 2.78 )
MYL' s 10-Year P/S Range
Min: 0.41   Max: 5.69
Current: 2.78

0.41
5.69
PFCF 24.60
MYL's PFCF is ranked higher than
89% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 24.60 )
MYL' s 10-Year PFCF Range
Min: 8.81   Max: 82
Current: 24.6

8.81
82
EV-to-EBIT 23.15
MYL's EV-to-EBIT is ranked higher than
80% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.81 vs. MYL: 23.15 )
MYL' s 10-Year EV-to-EBIT Range
Min: 6.6   Max: 28.8
Current: 23.15

6.6
28.8
PEG 4.40
MYL's PEG is ranked higher than
80% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 367.50 vs. MYL: 4.40 )
MYL' s 10-Year PEG Range
Min: 0.37   Max: 11.64
Current: 4.4

0.37
11.64
Shiller P/E 48.00
MYL's Shiller P/E is ranked higher than
82% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 48.00 )
MYL' s 10-Year Shiller P/E Range
Min: 12.15   Max: 79.39
Current: 48

12.15
79.39
Current Ratio 1.64
MYL's Current Ratio is ranked higher than
60% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. MYL: 1.64 )
MYL' s 10-Year Current Ratio Range
Min: 1.39   Max: 8.52
Current: 1.64

1.39
8.52
Quick Ratio 0.98
MYL's Quick Ratio is ranked higher than
54% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MYL: 0.98 )
MYL' s 10-Year Quick Ratio Range
Min: 0.85   Max: 6.76
Current: 0.98

0.85
6.76

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.50
MYL's Price/DCF (Projected) is ranked higher than
85% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 2.50 )
MYL' s 10-Year Price/DCF (Projected) Range
Min: 0.62   Max: 2.51
Current: 2.5

0.62
2.51
Price/Median PS Value 1.50
MYL's Price/Median PS Value is ranked higher than
60% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. MYL: 1.50 )
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.73
Current: 1.5

0.36
3.73
Price/Peter Lynch Fair Value 3.60
MYL's Price/Peter Lynch Fair Value is ranked higher than
87% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 3.60 )
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67   Max: 10.2
Current: 3.6

0.67
10.2
Earnings Yield (Greenblatt) 4.30
MYL's Earnings Yield (Greenblatt) is ranked higher than
69% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. MYL: 4.30 )
MYL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 15
Current: 4.3

3.5
15
Forward Rate of Return (Yacktman) 10.84
MYL's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. MYL: 10.84 )
MYL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.4   Max: 38.9
Current: 10.84

3.4
38.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MYL.Germany
Mylan, Inc. was incorporated in Pennsylvania in 1970. The Company and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic and branded generic pharmaceuticals, specialty pharmaceuticals and active pharmaceutical ingredients. The Company has two reportable segments, the Generics Segment and the Specialty Segment. The principal markets for the Generics Segment products are proprietary and ethical pharmaceutical wholesalers and distributors, drug store chains, drug manufacturers, institutions, and public and governmental agencies primarily within the United States and Canada, Europe, the Middle East and Africa, Australia, Japan, India and New Zealand. The Generics Segment also develops active pharmaceutical ingredients with non-infringing processes to partner with generic manufacturers in regulated markets such as the U.S. and European Union at market formation. The principal market for the Specialty Segment products is pharmaceutical wholesalers and distributors, pharmacies and health care institutions primarily in the U.S. The specialty business is engaged respiratory, allergy and psychiatric therapies. The Company's active pharmaceutical ingredient business is conducted through Mylan Laboratories Limited. It also manufactures and supplies low cost, high quality active pharmaceutical ingredients for its own products and pipeline, as well as for third parties. During 2012, it completed more than 690 global country level product submissions, which included 88 in North America, 375 in EMEA and 229 in Asia Pacific. The Company's EPIPEN Auto-Injector is the number one prescribed epinephrine auto-injector. It markets a global portfolio of approximately 1,100 different products covering a vast array of therapeutic categories. In the U.S., the company has products portfolio consisting of approximately 365 products, of which approximately 310 are in capsule or tablet form in an aggregate of approximately 880 dosage strengths. Included in these totals are approximately 40 extended-release products in a total of approximately 105 dosage strengths.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Scott Black’s Top First Quarter Holdings Apr 23 2014 
Should You Buy Actavis? Mar 18 2014 
Scott Black’s Top Five Stocks at Year End Jan 09 2014 
Scott Black’s Top Five Third Quarter Holdings Oct 22 2013 
S&P Winners Broadly Held by Billionaires Oct 06 2013 
Weekly CEO Sells Highlight: Workday Inc., Kirby Corp., Mylan Inc., Infinera Corporation Sep 09 2013 
Three Stocks for a Recovering Europe Jul 29 2013 
comment on MYL Jan 03 2013 
comment on MYL Jan 01 2013 
Weekly Top Insider Sells: FIS, MYL, LMCA Dec 24 2012 


More From Other Websites
After Spurning a U.S. Inversion, Meda Buys in Europe Jul 31 2014
Meda to buy drugs maker Rottapharm for $3.08 billion Jul 31 2014
[$$] Sweden's Meda to Buy Italian Peer Jul 31 2014
How Obama Could End Walgreen's Tax-Inversion Hopes Jul 28 2014
Obama Calls Offshore Deals 'Unpatriotic' Yet Funds, Investors, Boards Jump Aboard Jul 27 2014
Walgreens eyes loophole end run around taxes Jul 26 2014
[video] Tax inversion debate: Can Congress fix it? Jul 25 2014
MARK CUBAN: If Your Company Is Moving For Tax Reasons, I'm Selling Your Stock Jul 25 2014
Obama calls on Congress to end inversion deals, NY Times reports Jul 25 2014
Mylan downgraded to Neutral from Buy at Citigroup Jul 25 2014
Did Congress prescribe Obamacare a 'poison pill?' Jul 24 2014
Obama to Make Campaign Pitch on Corporate Tax Avoidance Jul 24 2014
Mylan Wins Motion for Temporary Restraining Order Against Apotex for Authorized Generic of Paxil®... Jul 23 2014
[video] Father-daughter tax inversion battle Jul 23 2014
Who gets the last word on Obamacare? Jul 23 2014
Watch For Today's Momo Momentum Stock: Mylan (MYL) Jul 23 2014
[video] Faber Report: Inversion train rolling Jul 23 2014
Mylan wins restraining order against Apotex for generic version of GSK's Paxil Jul 23 2014
Mylan Wins Motion for Temporary Restraining Order Against Apotex for Authorized Generic of Paxil®... Jul 23 2014
[video] Don't Expect Tax Inversion Fever to Break Anytime Soon Jul 22 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide